Lilly Confident In Orforglipron Despite Disappointing Phase III Data

Oral GLP-1 Readout In Obesity Outweighed Q2 Earnings Beat

 
• By Mandy Jackson
  
Orforglipron still may be a blockbuster even if its data is not quite as strong as oral semaglutide (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business